That's slightly misleading. The market structure as it is today confer a significant advantage (especially, in the drug development market) to big companies wi

That's slightly misleading. The market structure as it is today confer a significant advantage (especially, in the drug development market) to big companies with deep pockets who can survive the regulatory approval process. Therefore, selling to big biotech corporations is a completely viable business model, if you have a technology that has proven itself in early studies and the next step requires you either raising a lot of money and losing most of the control of the company, or selling to a big corporation, cash in on years of time and dedication. Another pain point, is the involvement of VCs in the biotech market. Most VCs don't like long term investments. long-term is riskier and other markets offer faster ROI compared to biotech. Therefore, most VCs start pushing for an acquisition in the early stage of the development. There aren't many VCs willing to wait 15 years for a drug / diagnostic product to be approved and reach the market.